The initiation of the Phase 1 clinical trial and treatment of the first lymphoma patient with MT-601 is a significant milestone for Marker Therapeutics. This progress demonstrates the company's commitment to advancing its T cell therapy program and has the potential to positively impact the stock price in the short term as investors may view this as a sign of progress and growth.